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Background: In heart failure (HF), renal dysfunction (RD) can result from irreversible intrinsic renal parenchymal disease, but can also represent 
HF-induced “functional” RD which can improve with correction of the underlying pathophysiologic derangements. Significant improvement in renal 
function (IRF) has been reported to occur commonly during the treatment of decompensated HF; however no methodology exists to prospectively 
identify which patients have reversible RD at baseline. The blood urea nitrogen to creatinine ratio (BUN/Cr) has been used clinically to differentiate 
“pre-renal” from intrinsic RD. We hypothesized that an elevated admission BUN/Cr may identify HF patients with reversible RD and thus a greater 
incidence of IRF with treatment.
Methods: Consecutive patients hospitalized at our institution with a primary discharge diagnosis of HF were reviewed. Inclusion required an 
admission B-type natriuretic peptide (BNP) >100 pg/mL. IRF was defined as a ≥20% increase in estimated glomerular filtration rate (GFR) at any 
time during the hospitalization.
Results: Of 901 patients meeting inclusion criteria, 279 (31%) experienced IRF with an average increase in GFR of 43.7 ± 27 ml/min/1.73m2. 
Baseline BUN/Cr was significantly associated with IRF (OR=1.4 per 10 increase, p<0.00001). This association persisted after adjustment for baseline 
GFR (1.4 per 10 increase, p<0.0001) and baseline characteristics associated with IRF with p<0.2 (age, race, hypertension, diabetes, ischemic 
HF etiology, loop diuretic dose, use of spironolactone, beta blockers, angiotensin converting enzyme inhibitors, EF, BNP, hemoglobin, sodium, and 
GFR; OR=1.4 per 10 increase, p=.004). When dichotomized as ≥ or < 20, BUN/Cr was also associated with significantly increased incidence of IRF 
(OR=1.9, p<0.0001) as was comparison of the top vs. bottom quartile (OR=2.7, p<0.0001).
Conclusions: Elevated BUN/Cr identifies decompensated HF patients with reversible RD at baseline. Further research is necessary to evaluate if 
these results are generalizable outside the setting of decompensated HF and if therapeutic strategies specifically targeted at patients with elevated 
BUN/Cr may improve renal function.
